We conclude that omega-3 fatty acids may be associated with lower inflammatory biomarkers among diabetic and cardiovascular patients .
The purpose of this systematic review and meta- analysis was to investigate omega-3 fatty acids ’ influence on 12 inflammatory biomarkers — LDL , HDL , total cholesterol , TG , HbA1c , Apo AI , Apo AII , Apo B , CRP , TNF-α , glucose , and fasting blood glucose among diabetic and cardiovascular disease ( CVD ) patients .
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
BACKGROUND Patients with elevated serum triglyceride ( TG ) levels often have elevations in non-high-density lipoprotein cholesterol ( non-HDL-C ) levels as well . The National Cholesterol Education Program Adult Treatment Panel III ( NCEP ATP III ) has identified non-HDL-C as a secondary therapeutic target in these patients , but treatment goals may not be reached with statin monotherapy alone . OBJECTIVE This study evaluated the effects on non-HDL-C and other variables of adding prescription omega-3-acid ethyl esters ( P-OM3 ; Lovaza , formerly Omacor [ Reliant Pharmaceuticals , Inc. , Liberty Corner , New Jersey ] ) to stable statin therapy in patients with persistent hypertriglyceridemia . METHODS This was a multicenter , r and omized , double-blind , placebo-controlled , parallel-group study in adults who had received > or = 8 weeks of stable statin therapy and had mean fasting TG levels > or = 200 and < 500 mg/dL and mean low-density lipoprotein cholesterol levels < or = 10 % above their NCEP ATP III goal . The study regimen consisted of an initial 8 weeks of open-label simvastatin 40 mg/d and dietary counseling , followed by 8 weeks of r and omized treatment with double-blind P-OM3 4 g/d plus simvastatin 40 mg/d or placebo plus simvastatin 40 mg/d . The main outcome measure was the percent change in non-HDL-C from baseline to the end of treatment . RESULTS The evaluable population included 254 patients , of whom 57.5 % ( 146 ) were male and 95.7 % ( 243 ) were white . The mean ( SD ) age of the population was 59.8 ( 10.4 ) years , and the mean weight was 92.0 ( 19.6 ) kg . At the end of treatment , the median percent change in non-HDL-C was significantly greater with P-OM3 plus simvastatin compared with placebo plus simvastatin ( -9.0 % vs -2.2 % , respectively ; P < 0.001 ) . P-OM3 plus simvastatin was associated with significant reductions in TG ( 29.5 % vs 6.3 % ) and very-low-density lipoprotein cholesterol ( 27.5 % vs 7.2 % ) , a significant increase in high-density lipoprotein cholesterol ( HDL-C ) ( 3.4 % vs -1.2 % ) , and a significant reduction in the total cholesterol : HDL-C ratio ( 9.6 % vs 0.7 % ) ( all , P < 0.001 vs placebo ) . Adverse events ( AEs ) reported by > or= 1 % of patients in the P-OM3 group that occurred with a higher frequency than in the group that received simvastatin alone were nasopharyngitis ( 4 [ 3.3 % ] ) , upper respiratory tract infection ( 4 [ 3.3 % ] ) , diarrhea ( 3 [ 2.5 % ] ) , and dyspepsia ( 3 [ 2.5 % ] ) . There was no significant difference in the frequency of AEs between groups . No serious AEs were considered treatment related . CONCLUSION In these adult , mainly white patients with persistent hypertriglyceridemia , P-OM3 plus simvastatin and dietary counseling improved non-HDL-C and other lipid and lipoprotein parameters to a greater extent than simvastatin alone
We conclude that omega-3 fatty acids may be associated with lower inflammatory biomarkers among diabetic and cardiovascular patients .
The purpose of this systematic review and meta- analysis was to investigate omega-3 fatty acids ’ influence on 12 inflammatory biomarkers — LDL , HDL , total cholesterol , TG , HbA1c , Apo AI , Apo AII , Apo B , CRP , TNF-α , glucose , and fasting blood glucose among diabetic and cardiovascular disease ( CVD ) patients .